Abstract

1
Legal & ethical compliance when sharing biospecimen across borders is a complex topic where few 2 researchers can claim a high degree of competence. It is therefore common that major research 3 projects contain a component with dedicated experts on research ethics. But despite this support it is 4 impossible to fully delegate responsibility of biobank governance to external experts. For researchers 5 it is therefore beneficial to learn about the most commonly encountered mistakes that prevent the 6 efficient utilization of samples and take steps to avoid them. 7
Although laws regulating research oversight have been implemented differently in every country, 8 there is a similarity of core principles founded on international charters. These core principles are 9 based on the concept of consent and actions taken by the biobank in regards to sample usage rely on 10 either an explicit or presumed consent. In interview studies among donors chief concerns among 11 donors are focused on privacy, efficient sample utilization and if donors are given access to 12 information generated from their samples. Despite a lack of clear evidence regarding which concern 13 takes precedent among donors, scientific as well as public discourse has largely focused on privacy 14 concerns and the right of donors to control the usage of their samples. 15 As a result biobank governance has taken a largely negative approach to uncertainties in sample 16 utilization. This mean that sample usage is likely to be restricted if there is any uncertainty if the 17 intended usage is in line with donor expectations. To help biobank professionals avoid making
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1
The risk of biobank samples being used in an inappropriate manner has received increasing attention 2 in scientific discourse. In comparison the threat of under-utilization of samples or an inability to 3 return the benefits of research to donors have received relatively little attention despite also being 4 among the chief concerns of interviewed donors (Hoeyer, 2008) . As a result biobank regulations 5 largely focus on prevention of the inappropriate usage of samples rather than mechanisms to 6 encourage their proper usage. Furthermore the genomic revolution means that pretty much any 7 sample can be considered to contain potentially identifiable personal data in the form of DNA. Taken  8 Hard and soft law, the key to international collaboration 28 The national legal framework of biobanking is often substantially different even between countries of 29 comparable jurisdictional systems (Kiehntopf & Krawczak, 2011) . To accommodate international 30 collaboration it is therefore necessary to rely on "soft law" or extra-legal means to bridge the gap 31 between the national legal systems which operate on a "one nation, one law, one project" 32 approach(Kaye, 2011). 33
When dealing with such matters it is therefore important to understand and recognize how research 34 is regulated by a combination of "hard law" and "soft law" where the terms can be defined as 35 follows: 36 Hard law is codified in legal text which makes it relatively straightforward for a trained expert to 5 access and identify the relevant laws. Soft law is on the other hand more flexible but makes it harder 6 to find and understand the regulatory mechanisms as it allows governmental and non-governmental 7 experts to update regulations and standards without requiring active engagement of law making 8 bodies, often these experts may be specified in hard law as bodies tasked with providing legally 9 binding regulations and decisions. Funding bodies are becoming an increasingly important source of 10 soft law by enforcing contracts requiring certain guidelines or procedures to be followed by 11 researchers given funding in order to be eligible for funding. 12
For European researchers, an important source of this kind of regulation is the EU funding program 13 managed by the European Commission. It requires applicants to state in their proposal that they will 14 conform to specific standards("Ethics -European Commission") where failure to comply mean that 15 the researcher will not be eligible to receive the funds provided by the grant. 16
Similar approaches are not only used for international projects, but are also a way for national 17 agencies to harmonize activities in nations where legislation is done at a regional or state level. These guidelines are defined by one selected group of experts (the National Research Council) who 25 delegate decisions to another group of experts (the ESCRO committee) which is charged with 26 deciding if there is a comparable set of checks and balances in the partner country in the form of a, 27 yet to be identified, third group of experts. These guidelines are a good example of how a soft law 28 approach with several layers reduces transparency in return for increased flexibility as guidelines, 29 review committees and research practitioners make up an ever-changing system of stakeholders. 30
Under such circumstances, collaboration is substantially more likely to be accepted between nations 31 where the respective authorities have had the possibility to become familiar with each other's 32 customs and traditions, and above all, where the legal requirements applicable to the matter have 33 been enacted as a result of international agreements. A lack of trust, harmonization, or the local 34 preferences of the committee may therefore significantly affect the outcome of an application for 35 the transfer of data or samples. Decisions by judicial authorities covering one of the partners in a 36 collaboration may also have an immediate impact on international collaboration as certain 37
procedures are deemed to be in conflict with national law. Consent as the basis of international collaboration 8 The signed consent form provides a receipt that verify that the donor has been provided with 9 sufficient information to make an informed consent when donating his or her samples. biobank would need to result in a presumed, broad or specific kind of consent (see table 1 ). In bio-28 ethicist literature, concepts such as "tiered" or "dynamic" consent are suggested as compromises 29 between specific or broad forms of consent. In practice these forms of consent can either be broad 30 or specific depending on whether the components of the consent is widely or narrowly specified. It is 31 however not always possible or feasible to obtain information from a known, informed and willing 32 donor. In some cases a presumed consent is necessary and several ethicists also argue that a consent 33 can never be truly informed unless strict requirements are met (Salvaterra et  The importance of the research aim is sufficient to justify conducting the study and is 23 evaluated on a case-by-case basis by an ethics committee. 24  The sensitivity of the data is evaluated on a case-by-case basis. Genetic information varies in 25 sensitivity based on its significance, ranging from very stringent protection to a lesser degree 26 of protection. 27  Generic research results are always released without specifically identification of individual 28 subjects. 29  "Opt-out" consent is allowed for subsequent or secondary studies. Every subject must be 30 guaranteed the possibility of withdrawing consent at any time. 31  Participants must have adequate means of involvement, such as encouraging participant 32 consultation or communicating information through the mass media prior to project 33 initiation. The multiple modes of involvement should be complementary as opposed to 34 mutually exclusive. It is especially important that forms of direct participation also be 35 available, for example by having population representatives serve on the ethics committees 36 that will decide on the approval of the research before it begins. 37  Measures to ensure transparency and supervision must be in place. Adequate supervisory, 38 procedural, and technical systems are necessary to guarantee information protection. 39
Further, it is highly advisable to have external and independent supervisory bodies 40 monitoring procedural correctness. 41
The reporting of planned or incidental findings 1 Another controversial subject with far reaching consequences for sample availability is whether 2 researchers should be obliged to return information on findings to the donor(Christenhusz, Devriendt 3 & Dierickx, 2013). There is currently no overall consensus on when to tell and when not to tell 4 participants of incidental findings (Viberg et al., 2014) . Careful planning of procedures to satisfy local 5 or national expectations are therefore necessary to ensure that donor interests are managed 6
properly. 7
Based on the conflicting opinions described by researchers conducting systematic reviews of the field 8 it would be foolhardy to claim that practitioners and ethicists are anywhere near a consensus in the 9
field ( This means that the researchers, when developing the consent form, must take care to ensure the 26 long term viability of the biobank and balance their obligations to donors with the scientific needs of 27 the project. A high level of reciprocity can for example not be offered in a biobank where a large 28 portion of the research is expected to be conducted by external researchers limited to anonymized 29 data to maintain privacy. It is therefore necessary that researchers make important decisions such as 30 coding(Hunter et al., 2012) versus anonymization before contacting potential donors for consent. 31
Failure to do so may otherwise result in major issues in the future as national laws on privacy or 32 obligations outlined in the consent form may prevent the efficient usage of biospecimen. 33
Concluding remarks
34
International collaboration relies on soft law connecting national legal systems, which creates an 35 environment which is inconsistent, unfair and often lacking in transparency. But replacing the soft 36 law with hard law may be even worse since a codification of overly restrictive standards into law may 37 stifle or outright halt scientific progress in regions within the jurisdiction of such laws("Data 38 overprotection," 2015). Furthermore, it is unlikely that hard law solutions would be able to possess 39 the necessary flexibility to keep up the pace with the rapid advancement of research and genomics. 40
As a researcher it is easy to become frustrated and avoid engaging in such a complex, and ever-1 changing field of work. But despite calls for harmonization it is unlikely that issues will be solved in 2 the immediate future. sharing bio-specimens (Mascalzoni et al., 2015) . 32
This does not preclude researchers from having to abide by the national law of each state involved in 33 international research collaborations and is far from an exhaustive list of tools to support 34 international sharing of samples. But it may provide an international research project with a common 35 foundation and framework, which make the project more easily acceptable to the national 36 authorities charged with reviewing projects. 37
The inherent adaptability of soft law also mean that international collaboration through soft law 38 mechanisms may steadily improve as experience is gained among stakeholders and thus alleviate the 39 need for global governance via codified hard law solutions within the field. If given time to adapt, 40 researchers and associated organizations might instead be able to contribute to a bottoms-up 41 harmonization of a soft global bioethical framework. 42 
